{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:33:31Z","timestamp":1772213611818,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002241","name":"MEXT | Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["16K07124"],"award-info":[{"award-number":["16K07124"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"MEXT | Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["19K07671"],"award-info":[{"award-number":["19K07671"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"MEXT | Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["18K15602"],"award-info":[{"award-number":["18K15602"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Under hypoxic conditions, nitroimidazoles can replace oxygen as electron acceptors, thereby enhancing the effects of radiation on malignant cells. These compounds also accumulate in hypoxic cells, where they can act as cytotoxins or imaging agents. However, whether these effects apply to cancer stem cells has not been sufficiently explored. Here we show that the 2-nitroimidazole doranidazole potentiates radiation-induced DNA damage in hypoxic glioma stem cells (GSCs) and confers a significant survival benefit in mice harboring GSC-derived tumors in radiotherapy settings. Furthermore, doranidazole and misonidazole, but not metronidazole, manifested radiation-independent cytotoxicity for hypoxic GSCs that was mediated by ferroptosis induced partially through blockade of mitochondrial complexes I and II and resultant metabolic alterations in oxidative stress responses. Doranidazole also limited the growth of GSC-derived subcutaneous tumors and that of tumors in orthotopic brain slices. Our results thus reveal the theranostic potential of 2-nitroimidazoles as ferroptosis inducers that enable targeting GSCs in their hypoxic niche.<\/jats:p>","DOI":"10.1038\/s42003-020-01165-z","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T10:02:45Z","timestamp":1597658565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-0252","authenticated-orcid":false,"given":"Naoyoshi","family":"Koike","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyo","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Hishiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-6336","authenticated-orcid":false,"given":"Makoto","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-1049","authenticated-orcid":false,"given":"Oltea","family":"Sampetrean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393\u2013410 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437\u2013447 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1874471011104040379","volume":"4","author":"R Sharma","year":"2011","unstructured":"Sharma, R. Nitroimidazole radiopharmaceuticals in hypoxia: Part II cytotoxicity and radiosensitization applications. Curr. Radiopharm. 4, 379\u2013393 (2011).","journal-title":"Curr. Radiopharm."},{"key":"1165_CR4","first-page":"5863","volume":"59","author":"JM Brown","year":"1999","unstructured":"Brown, J. M. The hypoxic cell: a target for selective cancer therapy\u2013eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59, 5863\u20135870 (1999).","journal-title":"Cancer Res."},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","volume":"25","author":"J Overgaard","year":"2007","unstructured":"Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25, 4066\u20134074 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clon.2007.03.010","volume":"19","author":"P Wardman","year":"2007","unstructured":"Wardman, P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol. 19, 397\u2013417 (2007).","journal-title":"Clin. Oncol."},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0360-3016(81)90460-0","volume":"7","author":"J Martin Brown","year":"1981","unstructured":"Martin Brown, J., Yu, N. Y., Brown, D. M. & Lee, W. W. SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Rad. Oncol. Biol. Phys. 7, 695\u2013703 (1981).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0360-3016(84)90335-3","volume":"10","author":"AM Rauth","year":"1984","unstructured":"Rauth, A. M. Pharmacology and toxicology of sensitizers: mechanism studies. Int. J. Rad. Oncol. Biol. Phys. 10, 1293\u20131300 (1984).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/j.1349-7006.2009.01195.x","volume":"100","author":"S Kizaka-Kondoh","year":"2009","unstructured":"Kizaka-Kondoh, S. & Konse-Nagasawa, H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 100, 1366\u20131373 (2009).","journal-title":"Cancer Sci."},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","volume":"24","author":"D Rischin","year":"2006","unstructured":"Rischin, D. et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-Tasman radiation oncolog. J. Clin. Oncol. 24, 2098\u20132104 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","volume":"46","author":"J Overgaard","year":"1998","unstructured":"Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5\u201385. Radiother. Oncol.\u00a046, 135\u2013146\u00a0(1998).","journal-title":"Radiother. Oncol."},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0360-3016(97)00327-1","volume":"39","author":"F Eschw\u00e8ge","year":"1997","unstructured":"Eschw\u00e8ge, F. et al. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Rad. Oncol. Biol. Phys. 39, 275\u2013281 (1997).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0360-3016(99)00054-1","volume":"44","author":"PW Grigsby","year":"1999","unstructured":"Grigsby, P. W. et al. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: final results of RTOG 80-05. Int. J. Rad. Oncol. Biol. Phys. 44, 513\u2013517 (1999).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","volume":"18","author":"NK Lytle","year":"2018","unstructured":"Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669\u2013680 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0360-3016(95)00040-6","volume":"33","author":"N Oya","year":"1995","unstructured":"Oya, N. et al. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int. J. Rad. Oncol. Biol. Phys. 33, 119\u2013127 (1995).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1269\/jrr.43.77","volume":"43","author":"M Kuwabara","year":"2002","unstructured":"Kuwabara, M. et al. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350). J. Radiat. Res. 43, 77\u201377 (2002).","journal-title":"J. Radiat. Res."},{"key":"1165_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-106","volume":"13","author":"H Yasui","year":"2013","unstructured":"Yasui, H. et al. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood\u2013brain barrier disruption. BMC Cancer 13, 106 (2013).","journal-title":"BMC Cancer"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1269\/jrr.46.363","volume":"46","author":"T Yahiro","year":"2005","unstructured":"Yahiro, T. et al. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J. Radiat. Res. 46, 363\u2013372 (2005).","journal-title":"J. Radiat. Res."},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.radonc.2008.03.002","volume":"87","author":"R Murata","year":"2008","unstructured":"Murata, R., Tsujitani, M. & Horsman, M. R. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother. Oncol. 87, 331\u2013338 (2008).","journal-title":"Radiother. Oncol."},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.radonc.2008.02.007","volume":"87","author":"K Karasawa","year":"2008","unstructured":"Karasawa, K. et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother. Oncol. 87, 326\u2013330 (2008).","journal-title":"Radiother. Oncol."},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ijrobp.2007.04.008","volume":"69","author":"Y Nishimura","year":"2007","unstructured":"Nishimura, Y. et al. Phase I\/II Trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung cancer (WJTOG-0002). Int. J. Rad. Oncol. Biol. Phys. 69, 786\u2013792 (2007).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro-Oncol. 19, 887\u2013896 (2017).","journal-title":"Neuro-Oncol."},{"key":"1165_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1593\/neo.11624","volume":"13","author":"O Sampetrean","year":"2011","unstructured":"Sampetrean, O. et al. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 13, 784\u2013IN3 (2011).","journal-title":"Neoplasia"},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1158\/1078-0432.CCR-04-1081","volume":"10","author":"SM Evans","year":"2004","unstructured":"Evans, S. M. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 10, 8177\u20138184 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2353\/ajpath.2010.091021","volume":"177","author":"EE Bar","year":"2010","unstructured":"Bar, E. E., Lin, A., Mahairaki, V., Matsui, W. & Eberhart, C. G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 177, 1491\u20131502 (2010).","journal-title":"Am. J. Pathol."},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1750-3639.2010.00460.x","volume":"21","author":"EE Bar","year":"2011","unstructured":"Bar, E. E. Glioblastoma, cancer stem cells and hypoxia: hypoxia regulates glioma stem cells. Brain Pathol. 21, 119\u2013129 (2011).","journal-title":"Brain Pathol."},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2007.12.033","volume":"132","author":"A Sakaue-Sawano","year":"2008","unstructured":"Sakaue-Sawano, A. et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487\u2013498 (2008).","journal-title":"Cell"},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ceb.2017.11.001","volume":"51","author":"M Gao","year":"2018","unstructured":"Gao, M. & Jiang, X. To eat or not to eat\u2014the metabolic flavor of ferroptosis. Curr. Opin. Cell Biol. 51, 58\u201364 (2018).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1371\/journal.pbio.0050211","volume":"5","author":"D Leitsch","year":"2007","unstructured":"Leitsch, D., Kolarich, D., Wilson, I. B. H., Altmann, F. & Duch\u00eane, M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol. 5, e211 (2007).","journal-title":"PLoS Biol."},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tibs.2015.11.012","volume":"41","author":"AR Bogdan","year":"2016","unstructured":"Bogdan, A. R., Miyazawa, M., Hashimoto, K. & Tsuji, Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 41, 274\u2013286 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"24393","DOI":"10.18632\/oncotarget.5162","volume":"6","author":"M-Y Kwon","year":"2015","unstructured":"Kwon, M.-Y., Park, E., Lee, S.-J. & Chung, S. W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6, 24393\u201324403 (2015).","journal-title":"Oncotarget"},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.bbabio.2008.12.008","volume":"1787","author":"VP Skulachev","year":"2009","unstructured":"Skulachev, V. P. et al. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta 1787, 437\u2013461 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbabio.2010.03.015","volume":"1797","author":"VP Skulachev","year":"2010","unstructured":"Skulachev, V. P. et al. Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs). Biochim. Biophys. Acta 1797, 878\u2013889 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","volume":"417","author":"MP Murphy","year":"2009","unstructured":"Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J. 417, 1\u201313 (2009).","journal-title":"Biochem. J."},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1002\/cam4.1174","volume":"6","author":"N Minami","year":"2017","unstructured":"Minami, N. et al. Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. Cancer Med. 6, 2635\u20132645 (2017).","journal-title":"Cancer Med."},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/1097-0142(19810801)48:3<696::AID-CNCR2820480307>3.0.CO;2-V","volume":"48","author":"GE Adams","year":"1981","unstructured":"Adams, G. E. Hypoxia-mediated drugs for radiation and chemotherapy. Cancer 48, 696\u2013707 (1981).","journal-title":"Cancer"},{"key":"1165_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756\u2013760 (2006).","journal-title":"Nature"},{"key":"1165_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.stem.2010.12.012","volume":"8","author":"C Blanpain","year":"2011","unstructured":"Blanpain, C., Mohrin, M., Sotiropoulou, P. A. & Passegu\u00e9, E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8, 16\u201329 (2011).","journal-title":"Cell Stem Cell"},{"key":"1165_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/0360-3016(84)90530-3","volume":"10","author":"RC Urtasun","year":"1984","unstructured":"Urtasun, R. C., Coleman, C. N., Wasserman, T. H. & Phillips, T. L. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int. J. Rad. Oncol. Biol. Phys. 10, 1691\u20131696 (1984).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR40","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/0360-3016(84)90533-9","volume":"10","author":"DS Fulton","year":"1984","unstructured":"Fulton, D. S. et al. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int. J. Rad. Oncol. Biol. Phys. 10, 1709\u20131712 (1984).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/0360-3016(89)90939-5","volume":"16","author":"M Deutsch","year":"1989","unstructured":"Deutsch, M. et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int. J. Rad. Oncol. Biol. Phys. 16, 1389\u20131396 (1989).","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"1165_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298\u2013308 (2015).","journal-title":"Mol. Cell"},{"key":"1165_CR44","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73, 2195\u20132209 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"1165_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.niox.2013.09.005","volume":"35","author":"S Lin","year":"2013","unstructured":"Lin, S., Page, N. A., Fung, S. M. & Fung, H.-L. In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1. Nitric Oxide 35, 137\u2013143 (2013).","journal-title":"Nitric Oxide"},{"key":"1165_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0006-2952(86)90561-7","volume":"35","author":"JE Biaglow","year":"1986","unstructured":"Biaglow, J. E. et al. Biochemistry of reduction of nitro heterocycles. Biochem. Pharm. 35, 77\u201370 (1986).","journal-title":"Biochem. Pharm."},{"key":"1165_CR47","doi-asserted-by":"crossref","unstructured":"Wardman, P. Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. Br. J. Radiol. 20170915 10.1259\/bjr.20170915 (2018).","DOI":"10.1259\/bjr.20170915"},{"key":"1165_CR48","doi-asserted-by":"publisher","first-page":"33832","DOI":"10.18632\/oncotarget.26112","volume":"9","author":"S Okazaki","year":"2018","unstructured":"Okazaki, S. et al. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. Oncotarget 9, 33832\u201333843 (2018).","journal-title":"Oncotarget"},{"key":"1165_CR49","doi-asserted-by":"crossref","unstructured":"Otsuki, Y. et al. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT\u2010targeted therapy. Cancer Sci. 14224, 10.1111\/cas.14224 (2019).","DOI":"10.1111\/cas.14224"},{"key":"1165_CR50","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acs.jmedchem.7b01678","volume":"61","author":"M Bonnet","year":"2018","unstructured":"Bonnet, M. et al. Next-generation hypoxic cell radiosensitizers: nitroimidazole alkylsulfonamides. J. Med. Chem. 61, 1241\u20131254 (2018).","journal-title":"J. Med. Chem."},{"key":"1165_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03899-1","volume":"9","author":"M Shiota","year":"2018","unstructured":"Shiota, M. et al. Gold-nanof\u00e8ve surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival. Nat. Commun. 9, 1561 (2018).","journal-title":"Nat. Commun."},{"key":"1165_CR52","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Targeting ferroptosis to iron out cancer. Cancer Cell 35, 830\u2013849 (2019).","journal-title":"Cancer Cell"},{"key":"1165_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/ph11040120","volume":"11","author":"F Bou-Abdallah","year":"2018","unstructured":"Bou-Abdallah, F., Paliakkara, J., Melman, G. & Melman, A. Reductive mobilization of iron from intact ferritin: Mechanisms and physiological implication. Pharmaceuticals 11, 120 (2018).","journal-title":"Pharmaceuticals"},{"key":"1165_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/neuonc\/nox170","volume":"20","author":"S Shibao","year":"2018","unstructured":"Shibao, S. et al. Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model. Neuro-Oncol. 20, 343\u2013354 (2018).","journal-title":"Neuro-Oncol."},{"key":"1165_CR55","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/bjc.2014.378","volume":"111","author":"P Znojek","year":"2014","unstructured":"Znojek, P., Willmore, E. & Curtin, N. J. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br. J. Cancer 111, 1319\u20131326 (2014).","journal-title":"Br. J. Cancer"},{"key":"1165_CR56","first-page":"647","volume":"2016","author":"LC Crowley","year":"2016","unstructured":"Crowley, L. C. et al. Measuring cell death by propidium iodide uptake and flow cytometry. Cold Spring Harb. Prot. 2016, 647\u2013651 (2016).","journal-title":"Cold Spring Harb. Prot."},{"key":"1165_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms12308","volume":"7","author":"TM Ashton","year":"2016","unstructured":"Ashton, T. M. et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat. Commun. 7, 1\u201313 (2016).","journal-title":"Nat. Commun."},{"key":"1165_CR58","doi-asserted-by":"crossref","unstructured":"Faustino-Rocha, A. et al. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim. 10.1038\/laban.254 (2013).","DOI":"10.1038\/laban.254"},{"key":"1165_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nprot.2014.018","volume":"9","author":"JK Salabei","year":"2014","unstructured":"Salabei, J. K., Gibb, A. A. & Hill, B. G. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9, 421\u2013438 (2014).","journal-title":"Nat. Protoc."},{"key":"1165_CR60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.niox.2014.11.005","volume":"46","author":"M Ohmura","year":"2015","unstructured":"Ohmura, M. et al. Impacts of CD44 knockdown in cancer cells on tumor and host metabolic systems revealed by quantitative imaging mass spectrometry. Nitric Oxide 46, 102\u2013113 (2015).","journal-title":"Nitric Oxide"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01165-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01165-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01165-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:47:20Z","timestamp":1670381240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01165-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-01165-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S. has received commercial research grants from POLA Pharma Inc. and Nihon Noyaku Co. Ltd. O.S. has received research support from Nihon Noyaku Co. Ltd. The findings of this study are the subject of a Japanese patent application as follows: Applicants: Keio University and POLA Pharma Inc. Inventors: H.S., O.S., N.K., and N. Kubota. Application no.: PCT\/JP2018\/036792. Status: international publication. Specific aspects of the study covered in the application: radiosensitizing effect of doranidazole on GSCs as well as its effects on mitochondrial complexes and ROS. Doranidazole used in this study was provided by POLA Pharma Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"450"}}